Citadel Advisors LLC Buys Shares of 206,350 CeriBell (NASDAQ:CBLL)

Citadel Advisors LLC acquired a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 206,350 shares of the company's stock, valued at approximately $5,340,000. Citadel Advisors LLC owned 0.58% of CeriBell at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Rhumbline Advisers acquired a new position in shares of CeriBell during the fourth quarter worth $320,000. Bank of New York Mellon Corp acquired a new position in shares of CeriBell during the fourth quarter worth $628,000. Charles Schwab Investment Management Inc. acquired a new position in shares of CeriBell during the fourth quarter worth $2,500,000. PNC Financial Services Group Inc. acquired a new position in shares of CeriBell during the fourth quarter worth $47,000. Finally, Vanguard Group Inc. acquired a new position in shares of CeriBell during the fourth quarter worth $18,015,000.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 3,372 shares of CeriBell stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $15.03, for a total value of $50,681.16. Following the sale, the chief executive officer now owns 743,079 shares of the company's stock, valued at approximately $11,168,477.37. The trade was a 0.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $32.50.

CeriBell Price Performance

Shares of CBLL traded down $0.68 during mid-day trading on Friday, hitting $16.58. 211,770 shares of the company's stock were exchanged, compared to its average volume of 277,143. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The business's 50 day moving average is $17.15 and its two-hundred day moving average is $22.15.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. On average, equities research analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.